|Bid||0.0750 x 0|
|Ask||0.0700 x 0|
|Day's Range||0.0800 - 0.0800|
|52 Week Range||0.0650 - 0.1000|
|Beta (5Y Monthly)||2.97|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (ATTBF) announces the following updates on recent developments related to Abattis since the trading of the Company’s common shares on the Canadian Stock Exchange (the “CSE”) was halted on February 4, 2019 (the “Halt”). Since the Halt, the Company filed its audited annual financial statements and management discussion and analysis on August 8, 2019. Following this, on August 16, 2019, the Company filed its interim financial statements and management discussion and analysis for the first quarter ended December 31, 2018 and second quarter ended March 31, 2019.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (ATT.CN) (ATTBF) announces the filing of its annual financial statements for the year ended September 30, 2018 and is pleased to provide the following comprehensive update on recent developments related to Abattis since the trading of the Company’s common shares (each, a “Share”) was halted on the Canadian Securities Exchange (“CSE”) on February 4, 2019. After a long process, the Company has finally filed its annual financial statements, the related management discussion and analysis and the certification of the annual filings for the year ended September 30, 2018 (the “Annual Filings”).
Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce that, further to its news release dated April 2nd, 2019, the Company’s wholly-owned subsidiary, 1185277 B.C. Ltd. (the “Acquisition Subsidiary”) has successfully closed the acquisition (the “Acquisition”) of Pro Natura BV (“Pro Natura”). Abattis is also pleased to announce that it will be relaunching its Company Newsletter (the “Newsletter”), which has been designed to complement the Company’s continuous disclosure, and provide cannabis industry highlights as they pertain to the Company.
VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce that its wholly-owned subsidiary, 1185277 B.C. Ltd. (the "Acquisition Subsidiary"), has entered into a share purchase agreement (the "Agreement") to acquire (the "Acquisition") Pro Natura BV ("Pro Natura"), a privately held nutraceutical company based in Oisterwijk, Netherlands. Pro Natura has over 30 years of operations and sales experience in Europe, with over 100 products that have been marketed to both long-term repeat customers and new large groups of distributors. Pro Natura has been supported by a seasoned management team that still includes its original founder and has historically boasted €10M+ in per annum sales.
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2019) - Abattis Bioceuticals Corp (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") announces that, effective February 20, 2019 and March 6, 2019, both Wolfgang Richter and James Irving have respectively resigned as directors of the Company.The Company thanks both Mr. Richter and Mr. Irving for their service and wishes each all the best in their future endeavors.About Abattis Bioceuticals Corp.Abattis is positioned to be ...
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) provides the following update on the Company’s recent trading halt and upcoming conference call with Company management that was previously set for March 1, 2019. Further to the Company’s news release dated February 18, 2019, trading of the Company’s common shares continues to be halted on the Canadian Securities Exchange until the Company files its financial statements for the year ended September 30, 2018 (the “Financials”).
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to provide the following update on the Company’s recent trading halt and upcoming conference call with Company management set for March 1, 2019. On February 4, 2019, the trading of the Company’s common shares was halted due to the Company’s failure to file its year-end financial statements within the 90 day filing deadline required under National Instrument 51-102 – Continuous Disclosure Requirements. The Company is still undergoing its year-end financial statement audit and believes it will have them filed in the coming week.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that the temporary order from the British Columbia Securities Commission (“BCSC”), issued on November 26, 2018 (the “Order”), has not been extended against Abattis. “Abattis is very happy with the BCSC’s decision to remove the Company from the Order such that Abattis can continue to focus its efforts on revenue generation and building shareholder value” stated Rob Abenante, President and CEO of Abattis.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that, further to its new release dated December 7, 2018, the Company has entered into a definitive share exchange agreement (the “Agreement”) with 1157016 B.C. Ltd., dba NutriVida, a private arm’s length company incorporated in the Province of British Columbia (“NutriVida”), pursuant to which the Company will acquire 100% of the issued and outstanding common shares of NutriVida (the “Acquisition”). In consideration for the Acquisition, and on closing thereof, the Company will issue an aggregate of 58,823,529 common shares (each, a “Share”) in the capital of Abattis, pro rata, to the NutriVida shareholders at a deemed price of $0.085 per Share and make a cash payment of $250,000 as provided in the Agreement.
Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce the launch of its new website and provide an operational update. Abattis has recently unveiled its new marketing and branding materials, developed in conjunction with media company Canada One Communications Inc. (“Canada One”). Marketing materials include an updated website, corporate presentation and conference materials all highlighting Abattis’ new brand imagery (“new marketing materials”).
VANCOUVER, British Columbia, Dec. 18, 2018 /PRNewswire/ -- Abattis Bioceuticals Corp (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce its first proprietary product, Comfort, which has been produced through wholly owned subsidiary Vergence Naturals ("Vergence"). Abattis has teamed up with respected naturopathic doctor and nutraceuticals product developer Dr. Brazos Minshew to launch Comfort, a breakthrough nutraceutical combining traditional herbal remedies to safely and effectively address occasional pain. Released on Cyber Monday and set for introduction into the US and Canada in December 2018, the Comfort product is 100% owned by Vergence, and will be marketed under the newly-formed health and wellness brand.
Vancouver, British Columbia--(Newsfile Corp. - December 14, 2018) - CEO & President of Abattis Bioceuticals Corp., Robert Abenante, speaks on the medical marijuana company's many facets including: a vape line, extraction and laboratory services.If you cannot view the video above, please visit:https://www.b-tv.com/abattis-bioceuticals-ceo-clip-90sec/Abattis Bioceuticals Corp. is being featured on BNN Bloomberg on Dec. 15 - Dec. 16, 2018, throughout the day and evenings.Abattis Bioceuticals (CSE: ATT) (OCTQB: ATTBF)abattis.comAbout CEO Clips:CEO Clips is the largest library ...